Halozyme Therapeutics Inc HALO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer
HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Halozyme to Report Third Quarter 2026 Financial and Operating Results
Halozyme Wins Injunction Against Merck in Keytruda Patent Case — Update
Halozyme Granted Another Injunction Against Merck in Keytruda Patent Case
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
Trading Information
- Previous Close Price
- $96.50
- Day Range
- $94.98–96.89
- 52-Week Range
- $61.23–133.73
- Bid/Ask
- $95.93 / $96.03
- Shares Outstanding
- 114.01M
- Market Cap
- $10.92B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 18.71
- Price/Sales
- 6.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 3.64%
Company Profile
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 423
- Website
- https://www.halozyme.com
Valuation
Metric | HALO |
|---|---|
Price/Earnings (Normalized) | 18.71 |
Price/Book Value | — |
Price/Sales | 6.81 |
Price/Cash Flow | 12.09 |
Price/Earnings
HALO
Financial Strength
Metric | HALO |
|---|---|
Quick Ratio | 3.36 |
Current Ratio | 3.88 |
Interest Coverage | 30.70 |
Quick Ratio
HALO
Profitability
Metric | HALO |
|---|---|
Return on Assets (Normalized) | 29.29% |
Return on Equity (Normalized) | 458.40% |
Return on Invested Capital (Normalized) | 33.40% |
Return on Assets
HALO
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|ymD<rk | LOCK|n#C>Z | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|qSX@>Dx | LOCK|mK&<d | $99B | |||
| Moderna Inc MRNA | LOCK|f^LGL& | LOCK|^! | $87B | |||
| argenx SE ADR ARGX | LOCK|tjmK$v | LOCK|N^ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|t^&XQ>! | LOCK|>&X | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|?jVR&L?^ | LOCK|PQXsG | $31B | |||
| Incyte Corp INCY | LOCK|<MFT<Q> | LOCK|<$? | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|gwH>J# | LOCK|#Z!? | $21B | |||
| BioNTech SE ADR BNTX | LOCK|Hb@fj^? | LOCK|q$? | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|VP>B&?k | LOCK|&NH | $15B |